open access
Emicizumab (Hemlibra®) u chorych na hemofilię A powikłaną inhibitorem czynnika VIII — wytyczne Grupy ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów
open access
Abstract
W niniejszym artykule Grupa ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów przedstawiła zasady stosowania leku emicizumab. Emicizumab (Hemlibra ®, F. Hoffmann — La Roche, Bazylea, Szwajcaria) został dopuszczony do obrotu w krajach Unii Europejskiej w 2018 roku, a w Polsce jest dostępny dla chorych na hemofilię A powikłaną inhibitorem czynnika VIII od marca 2020 roku. Artykuł stanowi uzupełnienie wytycznych postępowania w hemofilii A i B powikłanej obecnością inhibitora czynnika VIII i IX, które ukazały się w 2017 roku.
Abstract
W niniejszym artykule Grupa ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów przedstawiła zasady stosowania leku emicizumab. Emicizumab (Hemlibra ®, F. Hoffmann — La Roche, Bazylea, Szwajcaria) został dopuszczony do obrotu w krajach Unii Europejskiej w 2018 roku, a w Polsce jest dostępny dla chorych na hemofilię A powikłaną inhibitorem czynnika VIII od marca 2020 roku. Artykuł stanowi uzupełnienie wytycznych postępowania w hemofilii A i B powikłanej obecnością inhibitora czynnika VIII i IX, które ukazały się w 2017 roku.
Keywords
emicizumab; hemofilia A; inhibitor; profilaktyka; krwawienia; wytyczne; Polska; czynnik VIII; czynniki omijające; rVIIa; aPCC
About this articleTitle
Emicizumab (Hemlibra®) u chorych na hemofilię A powikłaną inhibitorem czynnika VIII — wytyczne Grupy ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów
Journal
Journal of Transfusion Medicine
Issue
Article type
Guidelines / Expert consensus
Pages
153-164
Published online
2020-12-03
Bibliographic record
Journal of Transfusion Medicine 2020;13(3):153-164.
Keywords
emicizumab
hemofilia A
inhibitor
profilaktyka
krwawienia
wytyczne
Polska
czynnik VIII
czynniki omijające
rVIIa
aPCC
Authors
Jerzy Windyga
Krzysztof Chojnowski
Anna Klukowska
Paweł Łaguna
Magdalena Łętowska
Andrzej Mital
Wojciech Młynarski
Jacek Musiał
Jacek Treliński
Anetta Undas
Tomasz Urasiński
Joanna Zdziarska
Maria Podolak-Dawidziak
References (35)- Windyga J, Chojnowski K, Klukowska A, et al. Część II: Wytyczne postępowania w hemofilii A i B powikłanej inhibitorem czynnika VIII i IX (2 wydanie). Acta Haematol Pol. 2017; 48(3): 137–159.
- Blair HA. Emicizumab: a review in Hemophilia A. Drugs. 2019; 79: 1697–1707.
- Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017; 117(07): 1348–1357.
- Lenting P, Denis C, Christophe O. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood. 2017; 130(23): 2463–2468.
- Hemlibra® charakterystyka produktu leczniczego. https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_pl.pdf.
- Yoneyama K, Schmitt C, Kotani N, et al. A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. Clini Pharmacokinet. 2017; 57(9): 1123–1134.
- Kiialainen A, Schmitt C, Oldenburg J, et al. Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) without FVIII inhibitors receiving emicizumab once weekly in the phase 3 HAVEN 3 study [abstract no. P022] Haemophilia. 2019; 25(Suppl 1): 46–47.
- Kiialainen A, Schmitt C, Adamkewicz JI, et al. Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) receiving emicizumab every 2 or 4 weeks [abstract no. P021] Haemophilia. 2019; 25(Suppl 1): 45–46.
- Oldenburg J, Mahlangu J, Kim B, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017; 377(9): 809–818.
- Young G, Liesner Ri, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019; 134(24): 2127–2138.
- Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018; 379(9): 811–822.
- Pipe S, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. The Lancet Haematology. 2019; 6(6): e295–e305.
- Shima M, Nogami K, Nagami S, et al. Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study). Blood. 2018; 132(Supplement 1): 1186–1186.
- Jimenez-Yuste V, Klamroth R, Castaman G, et al. et al.. A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results [abstract no. OC 60.3]. Res Pract Thromb Haemost. 2019; 3(Suppl 1): 116–117.
- Kizilocak H, Yukhtman CL, Marquez-Casas E, et al. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019; 10: 2040620719860025.
- Batsuli G, Zimowski KL, Tickle K, et al. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia. 2019; 25(5): 789–796.
- Seaman C, Ragni M. Emicizumab use in major orthopedic surgery. Blood Adv. 2019; 3(11): 1722–1724.
- Santagostino E, Mancuso M, Novembrino C, et al. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica. 2019; 104(8): e380–e382.
- Okamoto S, Suzuki N, Suzuki A, et al. Successful Perioperative Combination of High-Dose FVIII Therapy Followed by Emicizumab in a Patient with Hemophilia A with Inhibitors. TH Open. 2019; 3(4): e364–e366.
- Dargaud Y, Lienhart A, Janbain M, et al. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica. 2018; 103(4): e181–e183.
- McCary I, Guelcher C, Kuhn J, et al. Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia. 2020; 26(4): 631–636.
- Ebbert P, Xavier F, Seaman C, et al. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia. 2019; 26(1): 41–46.
- Oldenburg J, Mahlangu JN, Bujan W, et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019; 25(1): 33–44.
- Hartmann R, Feenstra T, Valentino L, et al. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost. 2018 [Epub ahead of print].
- Gundabolu K, Goldsweig A, Bhatt V, et al. ST‐Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII. Haemophilia. 2019; 26(1).
- Levy G, Asikanius E, Kuebler P, et al. Safety analysis ofrFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from theHAVENclinical program. J Thromb Haemost. 2019; 17(9): 1470–1477.
- Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol. 2020.
- Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies. Blood. 2018; 132(Supplement 1): 633–633.
- Jenkins P, Bowyer A, Burgess C, et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia. 2019; 26(1): 151–155.
- Müller J, Pekrul I, Pötzsch B, et al. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A. Thromb Haemost. 2019; 119(09): 1384–1393.
- Peyvandi F, Kenet G, Pekrul I, et al. Laboratory testing in hemophilia: Impact of factor and non‐factor replacement therapy on coagulation assays. J Thromb Haemost. 2020; 18(6): 1242–1255.
- National Hemophilia Foundation. MASAC Document. ; 255: 2018.
- Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia. 2018; 24(3): 344–347.
- Susen S, Gruel Y, Godier A, et al. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia. 2019; 25(5): 731–737.
- Castaman G, Santoro C, Coppola A, et al. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus. 2020; 18(2): 143–151.